AB007. Bladder-sparing treatments for muscle-invasive bladder cancer
Podium Lecture

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer

Shengwen Li, Jianchen Wu, Zhiqiang Song, Haishan Shen, Qiang Li

Department of Urology, the First Hospital of Tsinghua University, Beijing 100016, China


Abstract: Radical cystectomy (RC) with pelvic lymph node dissection remains the gold-standard treatment for muscle-invasive bladder cancer (MIBC). Growing evidence suggests that bladder-sparing treatments may lead to acceptable oncologic outcomes in carefully selected patients and can offer improved quality of life through preservation of a functioning bladder. We summarize our clinical experience of bladder-sparing treatments for MIBC and review articles. MIBC patients with cT2 stage, unifocal tumor, absence of CIS or hydronephrosis are eligible for selective bladder preservation if they refuse or unfit for RC.

Keywords: Radical cystectomy (RC); muscle-invasive bladder cancer (MIBC); oncologic; selective bladder preservation


doi: 10.21037/tau.2017.s007


Cite this abstract as: Li S, Wu J, Song Z, Shen H, Li Q. Bladder-sparing treatments for muscle-invasive bladder cancer. Transl Androl Urol 2017;6(Suppl 3):AB007. doi: 10.21037/tau.2017.s007